Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment
DOI: https://doi.org/10.2147/ijgm.s460200
IF: 2.145
2024-06-05
International Journal of General Medicine
Abstract:Hua Liu, 1, 2, &ast Yang-Min Hao, 1, 2, &ast Sheng Jiang, 1, 2, &ast Maiheliya Baihetiyaer, 1, 2 Cheng Li, 3 Guo-Yao Sang, 4 Zhiming Li, 5 Guo-Li Du 1, 2, 6 1 State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia, Urumqi, Xinjiang, People's Republic of China; 2 Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 3 Data Statistics and Analysis Center of Operation Management Department, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 4 Laboratory Medicine Diagnostic Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 5 Department of Ultrasound, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 6 Bazhou People's Hospital, Korla, Xinjiang Uygur Autonomous Region, People's Republic of China &astThese authors contributed equally to this work Correspondence: Guo-Li Du, Email Purpose: This study aims to investigate the relationship between Sodium Glucose Co-transporter-2 inhibitors (SGLT2i) treatment and fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) combined with Type 2 Diabetes Mellitus (T2DM) and Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs). Methods: A case–control study was conducted, involving 280 patients with MASLD combined with T2DM treated at the First Affiliated Hospital of Xinjiang Medical University from January 2014 to October 2023. Among these patients, 135 received SGLT2i treatment. The association between the Fibrosis-4 (FIB-4) index and the occurrence of MACCEs, as well as the association between the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores and MACCEs, were evaluated. Results: The FIB-4 index and APRI scores were significantly lower in the SGLT2i treatment group compared to the non-SGLT2i group (1.59 vs 1.25, P < 0.001). SGLT2i treatment tended to reduce the occurrence of MACCEs compared to non-SGLT2i treatment (45.5% vs 38.5%, P =0.28). All patients who developed MACCEs in the non-SGLT2i treatment group had higher FIB-4 index (1.83 vs 1.35, P =0.003). Additionally, after SGLT2i treatment for a median duration of 22 months, patients showed significant reductions in blood glucose, APRI, and FIB-4 index. Conclusion: SGLT2i treatment significantly reduces the occurrence of MACCEs and liver fibrosis in patients with MASLD combined with T2DM. The FIB-4 index may serve as a potential surrogate marker for predicting the occurrence of MACCEs. Keywords: MASLD, type 2 diabetes mellitus, sodium-glucose co-transporter-2 inhibitors, MACCEs, FIB-4 index With the improvement of living standards, diabetes mellitus has become one of the most common chronic diseases in the world widely. 1 T2DM (Type 2 diabetes mellitus) is closely associated with cardiovascular diseases (CVD), including atherosclerosis, hypertension and heart failure. 2 CVD is the main cause of disability and disease burden globally, leading to premature mortality and increased health care costs. 3 Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), is recognized globally as a significant cause of chronic liver disease. The diagnosis of MASLD includes evidence of liver steatosis and at least one of the following five cardiac metabolic criteria: overweight or obesity, impaired glucose regulation or T2DM, hypertension, increased plasma triglycerides (TG) or decreased high-density lipoprotein cholesterol (HDL-c). 4 T2DM has long been recognized as an independent cardiovascular risk factor and is a common finding in MASLD. Approximately 60% of patients with T2DM have MASLD. 5,6 Furthermore, patients with T2DM combined with MASLD had a higher risk of CVD compared with patients with T2DM alone. This suggests a potential synergistic effect on cardiovascular disease occurrence in patients. 7,8 In the majority of patients, MASLD is closely associated with insulin resistance, hypertension, atherogenic dyslipidaemia, dysglycaemia and being overweight or obese, which are all established risk factors for CVD. 9–11 Conversely, previous studies have shown that the main cause of death in MASLD patients is CVD. 12 In addition, it is estimated that 20–30% of pat -Abstract Truncated-
medicine, general & internal